

<b>Reference number(s)</b>
1721-H

## SPECIALTY QUANTITY LIMIT PROGRAM

### ICLUSIG (ponatinib HCl)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Iclusig (ponatinib) 15 mg tablet	30 tablets per 30 days	Initial dosing: 45 mg orally once daily.  Initial dosing with strong CYP3A inhibitors or hepatic impairment (Child-Pugh A, B or C): 30 mg once daily.
Iclusig (ponatinib) 30 mg tablet	30 tablets per 30 days	
Iclusig (ponatinib) 45 mg tablet	30 tablets per 30 days	

#### III. REFERENCES

1. Iclusig [package insert]. Cambridge, MA: Ariad Pharmaceuticals, Inc.; October 2018.